Status:
COMPLETED
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate whether anemia prevention with NeoRecormon has an additional impact on reducing cardiovascular risk over conventional anemia treatment in patients mostly with stage IV chronic...
Eligibility Criteria
Inclusion
- adult patients \>=18 years of age;
- chronic renal anemia;
- not receiving renal replacement therapy.
Exclusion
- women who are pregnant or lactating;
- previous treatment with erythropoietin or other erythropoietic substance;
- blood transfusion within the last 3 months;
- need for dialysis expected in the next 6 months;
- administration of another investigational drug within 30 days preceding study start, or during the study.
Key Trial Info
Start Date :
July 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
605 Patients enrolled
Trial Details
Trial ID
NCT00321919
Start Date
July 1 2000
End Date
December 1 2004
Last Update
June 29 2016
Active Locations (93)
Enter a location and click search to find clinical trials sorted by distance.
1
Linz, Austria, 4020
2
Sankt Pölten, Austria, 3100
3
Brussels, Belgium, 1070
4
Brussels, Belgium, 1090